“ A recent study showed that Ketone supplementation significantly reduced androgen and glucose levels in women with PCOS, indicating the potential of ketone-based therapies as a new treatment, necessitating further clinical trials.”

Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with insulin resistance and elevated androgen levels. While ketogenic diets have been shown to reduce glucose and androgen levels in women with PCOS, the specific role of β-hydroxybutyrate (BHB), a key ketone body, had not been clearly established.

A randomized, placebo-controlled crossover trial involving 20 women with polycystic ovary syndrome (PCOS) found that BHB supplementation acutely lowered circulating androgen and glucose levels. Participants received either a ketone supplement or a taste-matched placebo. Following BHB intake, blood D-β-hydroxybutyrate (D-BHB) levels increased to 2.4±1.2 mM, compared to 0.1±0.1 mM in the placebo group.

BHB supplementation led to overall reductions in several androgens, including testosterone, free testosterone, androstenedione, and 11-ketotestosterone. Fasting plasma glucose also decreased to 4.6±0.7 mM after BHB intake, compared to 5.1±0.4 mM with placebo.

These results supported the potential of ketone-based therapies as a novel approach for managing PCOS and emphasized the need for long-term studies to assess their effectiveness further.

(Source:https://academic.oup.com/ejendo/advance-article-abstract/doi/10.1093/ejendo/lvaf106/8139130?redirectedFrom=fulltext&login=false)